All In Biotech

Drug Trial Radar · NCT07016074

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Nov 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
University of MichiganAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.

Conditions

  • Kidney Injury, Acute

Interventions

  • Sodium NitrateDrug

    The study drug is sodium nitrate capsule at a dose of 12mmol of nitrate. This medication will be given orally 1-8 hours before the planned contrast administration and then once per day for a total of four doses.

  • PlaceboDrug

    The placebo control medication will be a capsule filled with lactose that will be taken in the same manner and schedule as the sodium nitrate capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of participants receiving the first dose of blinded study drug within 1-8 hours prior to contrast exposureTime frame: Approximately 34 days
  2. Percent of participants completing full course of 4 doses of blinded study drugTime frame: Approximately 34 days
  3. Percent of participants with 48-hour basic metabolic panel collected between 36-108 hours of contrast exposureTime frame: Approximately 34 days
  4. Percent of participants who had completion of clinical outcome monitoring at 30-day follow-up interviewTime frame: Approximately 34 days
  5. Percent of participants recruited to the trial for undergoing coronary angiogramTime frame: Approximately 34 days
  6. Percent of participants recruited to the trial for undergoing a contrast-enhanced CT scanTime frame: Approximately 34 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.